SEC Form 4 · accession 0001231589-26-000016
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul A Mahon
Officer — EVP & GENERAL COUNSEL
Period of report
Jul 16, 2026
Accepted (ET)
Jul 16, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 16, 2026 | M | 8,300 | $146.03 | A | 53,472 | D | |
| Common Stock | Jul 16, 2026 | S | 600 | $527.595 | D | 52,872 | D | |
| Common Stock | Jul 16, 2026 | S | 120 | $529.81 | D | 52,752 | D | |
| Common StockF2 | Jul 16, 2026 | S | 861 | $531.9692 | D | 51,891 | D | |
| Common StockF3 | Jul 16, 2026 | S | 800 | $532.9394 | D | 51,091 | D | |
| Common StockF4 | Jul 16, 2026 | S | 3,279 | $534.2114 | D | 47,812 | D | |
| Common StockF5 | Jul 16, 2026 | S | 1,041 | $535.8798 | D | 46,771 | D | |
| Common StockF6 | Jul 16, 2026 | S | 1,519 | $534.9891 | D | 45,252 | D | |
| Common StockF7 | Jul 16, 2026 | S | 80 | $536.8526 | D | 45,172 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $146.03 | Jul 16, 2026 | M | 8,300 | D | Mar 15, 2023 | Mar 15, 2027 | Common Stock | 8,300 | 80,740 | D |
Explanation of responses
- F1This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $531.50 to $532.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $532.51 to $533.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $533.56 to $534.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $535.565 to $536.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $534.56 to $535.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $536.75 to $536.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.